Natural Alternatives International Inc
NAII Nasdaq· Medicinal Chemicals & Botanical Products
Last close · Oct 26, 2026
$1.15
KIRA · Stoqly’s AI analyst, in plain words
- Natural Alternatives International Inc had $143M of revenue in fiscal 2026, up 9.7% on the year before. Over five years, revenue changed −4.4% a year on average.
- Its operating margin was −13.2%, down 6.5 pts: of every 100 in sales, about −13 is left after running the business.
- Natural Alternatives International Inc lost $20.7M in fiscal 2026.
- Free cash flow was −$12.6M in fiscal 2026, −8.9% of revenue.
- Natural Alternatives International Inc returned $0.1M to shareholders in fiscal 2026. The diluted share count rose 1.4%.
Market cap
$6.9M
P/E
—
Revenue
$143M
Net income
−$20.7M
Free cash flow
−$12.6M
Operating margin
−13.2%
Natural Alternatives International Inc in 30 seconds · fiscal 2026
Are sales growing?
+9.7%
Yes. Sales grew 9.7% last year.
Does it make a profit?
−14.5%
No. It lost money last year.
Does profit turn into cash?
−8.9%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Natural Alternatives International Inc does
No business description yet.
- Fiscal year ends
- June 30, 2026
- Latest annual report
- 10-K · Sep 28, 2026
- Legal name
- NATURAL ALTERNATIVES INTERNATIONAL INC
- CIK
- 0000787253
Natural Alternatives International Inc · NAII
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $171M | $154M | $114M | $130M | $143M |
| Revenue growth | −4.2% | −9.9% | −26.1% | 14.1% | 9.7% |
| Net interest income | −$0.1M | −$0.5M | −$0.4M | −$0.9M | −$1.2M |
| Gross margin | 17.8% | 11.8% | 6.0% | 7.2% | 6.3% |
| Operating margin | 8.0% | 3.1% | −7.5% | −6.7% | −13.2% |
| Net income | $10.7M | $2.5M | −$7.2M | −$13.6M | −$20.7M |
| Net margin | 6.3% | 1.6% | −6.3% | −10.5% | −14.5% |
| Diluted EPS | $1.74 | $0.43 | −$1.23 | −$2.28 | −$3.43 |
| Cash | |||||
| Cash from operations | $11.9M | $7.0M | −$1.5M | $5.9M | −$8.9M |
| Capital expenditure | $26.5M | $13.5M | $3.0M | $3.6M | $3.7M |
| Free cash flow | −$14.6M | −$6.5M | −$4.5M | $2.3M | −$12.6M |
| FCF margin | −8.6% | −4.2% | −4.0% | 1.8% | −8.9% |
| Share buybacks | $5.5M | $1.5M | $0.2M | $0.2M | $0.1M |
| Share count change | −3.5% | −4.5% | −0.1% | 1.3% | 1.4% |
| Debt and strength | |||||
| Cash and short-term investments | $21.8M | $13.6M | $12.0M | $12.3M | $7.4M |
| Shareholders' equity | $88.5M | $88.8M | $82.6M | $68.4M | $50.0M |
| Current ratio | 3.2x | 3.6x | 2.6x | 2.1x | 1.7x |
| Returns and quality | |||||
| Return on equity | 12.7% | 2.8% | −8.4% | −18.0% | −35.0% |
| Return on tangible equity | 12.1% | 2.8% | −8.7% | −19.8% | −41.4% |
| Piotroski F-score | 5 | 5 | 2 | 4 | 2 |
| Altman Z'' | 6.4 | 6.2 | 3.7 | 3.1 | 2.1 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Natural Alternatives International Inc · NAII
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.15 a share, the company is worth $6.9M.
Source: SEC EDGAR XBRL filings (CIK 0000787253). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.